Olympus Launches AI-Powered Endoscopy Portfolio OLYSENSE CAD/AI
Olympus Europa SE & Co. KG has launched its first cloud-based AI portfolio, OLYSENSE CAD/AI, to enhance patient outcomes and clinical efficiency across various diseases. The portfolio, commercially available in Germany, France, and the UK, comprises three approved apps: CADDIE, CADU, and SMARTIBD.
OLYSENSE CAD/AI harnesses AI to detect and characterise tissues and lesions in endoscopy procedures. The initial apps target different conditions:
CADDIE, a colonoscopy assistant, improves adenoma detection rate by 7.4% and aids in finding hard-to-spot, high-risk polyps. It supports early detection of colorectal cancer.
CADU focuses on Barrett's Esophagus, highlighting areas with the highest likelihood of dysplasia in endoscopy images, aiding accurate clinical decisions.
SMARTIBD assists in Ulcerative Colitis analysis, aligning with the MAYO scoring system.
The launch of OLYSENSE marks the first step towards creating Olympus's intelligent endoscopy ecosystem, aiming to boost clinical and operational performance in healthcare.
The OLYSENSE CAD/AI portfolio, commercially launched in three European countries, uses AI to enhance endoscopy procedures and patient outcomes. It marks the beginning of Olympus's intelligent endoscopy ecosystem, with potential to improve clinical efficiency across various diseases.
